發展對急性髓細胞性白血病和白血病幹細胞能診療一貫之奈米標靶藥物並臨床治療前評價(1/3)

Medicine & Life Sciences

1. Leukemia 100%
2. haptoglobin-hemoglobin complex 54%
3. Calicheamicins 53%
4. Neoplasms 49%
5. Multifunctional Nanoparticles 49%
6. Stem Cells 44%
7. Clinical Trials 39%
8. Scavenger Receptors 39%
9. Nanomedicine 38%
10. Drug Industry 35%
11. Carcinoembryonic Antigen 34%
12. Cell Adhesion Molecules 33%
13. Oncologists 33%
14. Drug Liberation 29%
15. Acute Myeloid Leukemia 29%
16. Drug Development 28%
17. Pancreatic Neoplasms 28%
18. Heterografts 27%
19. Cell Biology 26%
20. Anti-Idiotypic Antibodies 25%
21. Pharmaceutical Preparations 25%
22. Hemoglobins 24%
23. Colorectal Neoplasms 24%
24. Survival Rate 23%
25. Anti-Bacterial Agents 20%
26. Breast Neoplasms 19%
27. Drug Therapy 17%
28. Recurrence 17%
29. Survival 16%
30. Mortality 15%
31. Therapeutics 15%